SCHEMBL7751795

SCHEMBL7751795

CCOC(OCC)(P=O)c1ccc(C(=O)OC)cc1

nearest known ligand 0.49

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
MAPT P10636 4/20 0.49
CA1 P00915 4/20 0.44
CA2 P00918 4/20 0.44
TDP1 Q9NUW8 1/20 0.44
CA12 O43570 1/20 0.44
CA7 P43166 1/20 0.44
CA9 Q16790 1/20 0.44
CA14 Q9ULX7 1/20 0.44
LOXL2 Q9Y4K0 1/20 0.44
HPGD P15428 1/20 0.43
MEN1 O00255 1/20 0.42
KMT2A Q03164 1/20 0.42
TSHR P16473 1/20 0.42
ALDH1A1 P00352 2/20 0.41
POLB P06746 1/20 0.41
CYP4A11 Q02928 2/20 0.41
LMNA P02545 1/20 0.40
CYP4F2 P78329 1/20 0.40
RAB9A P51151 1/20 0.40

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL4712192 0.87 CA1 (0.50) MAPTCA1CA2TDP1CA12
SCHEMBL4689119 0.84 MEN1 (0.46) MAPTCA1CA2MEN1KMT2A
SCHEMBL2208167 0.83 MAPT (0.47) MAPTCA1CA2TDP1CA12
SCHEMBL498352 0.82 LOXL2 (0.46) MAPTCA1CA2CA12CA9
SCHEMBL27487116 0.81 CFTR (0.41) MAPTCA1CA2TDP1CA12
SCHEMBL2574861 0.78 ESR1 (0.44) CA1CA2CA12CA7CA9
SCHEMBL28113312 0.77 TDP1 (0.44) MAPTTDP1HPGDMEN1KMT2A
SCHEMBL7751798 0.75 MAPT (0.49) MAPTCA1CA2TDP1CA12
SCHEMBL28149485 0.75 LMNA (0.33) MAPTCA1CA2CA9HPGD
SCHEMBL18394314 0.74 ALDH1A1 (0.48) MAPTTDP1HPGDMEN1KMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-1293034-C New gamma selective retinoids HOFFMANN LA ROCHE (CH) 2007-01-03 CN disclosed
CN-1430596-A New gamma selective retinoids HOFFMANN LA ROCHE (CH) 2003-07-16 CN disclosed
US-20010034448-A1 New compounds, their preparation and use MURRAY ANTHONY (GB) 2001-10-25 US disclosed
CN-1302292-A Aminoisoquinoline derivatives AJINOMOTO KK (JP) 2001-07-04 CN disclosed
EP-1077920-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 2001-02-28 EP disclosed
CN-1243505-A Benzamidine derivatives AJINOMOTO KK (JP) 2000-02-02 CN disclosed
WO-1999058487-A1 NEW COMPOUNDS, THEIR PREPARATION AND USE NOVO NORDISK A/S (DK) 1999-11-18 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20010034448-A1 New compounds, their preparation and use GPR119, SLC5A1, SLC5A2 MAPT 3618/4885CA1 3435/4885CA2 1626/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.